GLPwatch
Weight Loss in Adults Using Semaglutide (Real-world Study)
NCT07627074 · Recruiting
Last updated 2026-07-13This study is testing how well semaglutide helps adults with overweight or obesity lose weight in real-world settings.
Status Recruiting Currently enrolling participants.
Type Observational
Participants 35,000 people Planned (estimated).
Who can join Ages 18+ · all sexes
Timeline Started 2026-05 · est. completion 2026-06
Where 2 sites · United Kingdom, United States
What this study is testing ClinicalTrials.gov NCT07627074 ↗
Description as written by the study sponsor.
The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.
Treatments tested
- Semaglutide Drug
This is a retrospective, non-interventional study; therefore, no intervention was administered as part of the study.
| Main thing measured | Change in body weight |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Conditions studied | Overweight, Obesity |
| GLP-1 drugs | semaglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07627074 ↗